Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

Inflammation Expert Opinions Lina Badimon explica por qué el bloqueo de la inflamación puede representar un beneficio clínico significativo, debido al importante papel de la inflamación en la formación de la placa aterosclerótica. Los resultados de CANTOS pueden representar el inicio de una nueva era en la prevención cardiovascular.

Educational information

The CANTOS trial is the first in a series of trials that test the hypothesis that inhibiting inflammation can lower residual CV risk. The results of this trial indeed confirm this hypothesis, suggesting that from now on, targeting inflammation may need to be considered in patients on lipid-lowering therapy with residual inflammatory CV risk.

These inflammation expert opinion videos are aimed to provide guidance and perspectives on the implications of the CANTOS trial and other trials addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.

This recording was developed under auspices of PACE-cme.

The views expressed in this recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Disclosures

Prof. Lina Badimon is the Director of the Cardiovascular Science Institute (ICCC) in Barcelona in the Hospital Santa Creu and San Pau, Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona and Director of the UNESCO Chair in Biomedical Sciences Training and Research.

Funding

Funding to produce this video was provided by an unrestricted educational grant from Novartis.